Nausea management GLP-1 nausea typically peaks during the first few weeks at each new dose level
dose ramp-up, Dosing, and Handling Discontinuation or Rebound Weight Gain Slow dose ramp-up reduces nausea and improves tolerability
What the Research Shows GLP-1 receptor agonists work by slowing gastric emptying, reducing appetite, and improving insulin sensitivity
[28] [29] Before starting GLP-1 therapy, your healthcare provider will: Review your complete medical history, including thyroid disease status Ensure thyroid function is optimised Assess for any contraindications Discuss the benefits and risks specific to your situation With appropriate patient selection and monitoring, GLP-1 receptor agonists can be safely prescribed to individuals with Hashimoto's disease when the clinical benefits outweigh potential risks
doi: 10.1007/s11102-022-01258-4 25 WitekPZieliskiGMaksymowiczMZgliczyskiW
IGF-1 LR3, also known as Insulin-Like Growth Factor-1 Long R3, is a synthetic IGF-1 analog that has been investigated in published scientific literature involving peptide biology, receptor signaling, molecular biology, protein expression, peptide chemistry, cellular communication, and experimental laboratory models